300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Renewable Energy
Software
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Music
Art
Real Estate
Sporting Goods
Manufacturing
Life Science
Digital Media
FinTech
Finance
Wine and Spirits
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Food and Beverage
Publishing
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Mexico
Tunisia
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Sweden
Romania
Zimbabwe
Zambia
Norway
Tajikistan
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Sudan
Andorra
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Nicaragua
Mauritius
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Seychelles
Moldova
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United States
United Kingdom
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Partners Innovation Fund, VC Fund

Partners Innovation Fund

VC Fund

Boston, United States

Partners Innovation Fund is a VC fund in Boston focused on Biotechnology and Health Care. The Innovation Fund was created in 2007 by Brigham and Women's Hospital and Massachusetts General Hospital to address a growing unmet need for funding emerging technology in the capital gap between invention and product development.The main objective of the fund is to accelerate to market technologies developed by Partners HealthCareinvestigators, thereby enhancing healthcare quality, cost and outcomes. Structured as a separate LLC entity, the $35M Fund is evergreen in design and will reinvest all gains from investments back into the Fund to create capital for additional investments.Investment decision oversight is provided by an independent external committee composed of experts from industry, venture capital and academia.The Fund operates on a venture capital model whereby opportunities are rigorously evaluated on the basis of scientific strength as well as potential for commercial success.The Fund has four major goals:* Capture more value from the PHS research portfolio by creating companies, technologies and solutions that advance and enhance healthcare.* Provide funding for technologies positioned in the capital gap between invention and clinical development.* By demonstrating institutional commitment, attract external capital that will leverage and encourage co-investment.* Generate a return on investment to refresh the fund and provide capital for additional technologies.Gap FundingOver the last five to seven years, the environment for early-stage investing has undergone significant change. As a result of these changes, there is a dearth of funding support for technologies/companies positioned between invention and clinical development. By focusing on this capital gap, the Fund can advance technologies of high commercial potential and medical benefit to a stage where larger, more traditional investment sources are attracted to underwrite the risk.Types of Fund InvestmentsThe Partners Innovation Fund will make two types of investments: Equity and Development.Equity investments are seed and early financings that will catalyze company formation. These investments will often be a Series A stock and co-investors are frequently other early institutional investors, private investors or corporate investment funds.Development investments precede company formation and are intended to validate technologies with a high potential for later commercialization by either new venture formation or out-licensing to an existing market player.For all investments, funds will be reserved for participation in follow-on investments.Innovation Fund ProcessUtilizing a proven venture capital based diligence model, the team conducts in-depth diligence on all opportunities in two steps:1. Initial Screening: Assesses opportunities for high commercial potential. Key project attributes are:* Product concept and value proposition* Intellectual Property Position* Stage of technology development* Market Opportunity* Technology Review* Management Team* Regulatory pathway* Funding requirements* Competitive Analysis* Business Model 2. Evaluation and Investment Decision: During this step, PIF staff conducts extensive diligence to assess the strength of the proposed business in relation to our investment criteria. This process takes place over 3 to 6 months during which time we interact with technical and market experts, possible customers, competitors and potential co-investors as we prepare for presentation of the investment opportunity to our external Investment Committee for final approval.The team will work with investigators and their advisors to develop a project or business plan including connections to potential entrepreneurs, advisors and investors in the venture, private or corporate arena.Venture Launch / Ongoing Support: Once an investment has been approved, the Innovation Fund plays an active role in the ongoing development of the new venture. The team will work on all aspects required to move the new entity forward including recruiting senior management and staff, providing guidance and support in technology development, serving on the Board of Directors and working with management to achieve milestones.

Total investments:
47
Last investment:
Lead investor:
9%
Fund size:
$171M
Last fund:

Last updated:

Industries Partners Innovation Fund invests in

BiotechnologyHealth CareTherapeuticsMedicalPharmaceutical

Stages Partners Innovation Fund invests in

Series ASeries BSeedSeries CSeries D

Countries Partners Innovation Fund invests in

United StatesFrance

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Biotechnology 24 (51%)
  • Health Care 18 (38%)
  • Therapeutics 11 (23%)
  • Medical 10 (21%)
  • Pharmaceutical 6 (13%)
See all 19 industries →

Stage

  • Series A 24 (51%)
  • Series B 8 (17%)
  • Seed 3 (6%)
  • Series C 2 (4%)
  • Series D 2 (4%)
See all 8 stages →

Country

  • United States 27 (57%)
  • France 1 (2%)

Team

NameTitleInvestmentsLinksEmail
Anne C. Pareti
Anne C. Pareti Associate II
Associate II Total investments: 0
Find email
Ellen Jung
Ellen Jung Associate II
Associate II Total investments: 0
Find email
Jessica M. Jacobs
Jessica M. Jacobs Associate, Research & Licensing
Associate, Research & Licensing Total investments: 0
Find email
Michael Band
Michael Band Manager, Business Development
Manager, Business Development Total investments: 0
Find email
Pamela Keddy Executive Assistant
Executive Assistant Total investments: 0
Find email
See all 8 team members →

Investments

CompanyDescriptionRoundLinks
Pykus Therapeutics Pykus Therapeutics
Pykus Therapeutics, Inc. was founded in 2016 to develop a dissolvable intraocular surgical device to make retinal surgery less painful and more successful.The co-founders were ophthalmology residents at the Massachusetts Eye and Ear Infirmary and Harvard Medical School when they developed a novel hydrogel to replace the use of intraocular gasduring retinal surgery. This innovation will eliminate the extreme burden placed on patients including the requirement for face-down positioning, inability to see for weeks, and inability to fly for weeks. $2.5M / Venture - Series Unknown / Feb 04, 2021
Verve Therapeutics Verve Therapeutics
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids suchas low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. $63M / Series A / Jun 11, 2020
ROME Therapeutics ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. $50M / Series A / Apr 27, 2020
ROME Therapeutics ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. $50M / Series A / Apr 27, 2020
SwanBio Therapeutics SwanBio Therapeutics
SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders. $52M / Series A / Apr 23, 2020
Affinia Therapeutics Affinia Therapeutics
Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle andcentral nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties. $60M / Series A / Mar 31, 2020
Keros Therapeutics Keros Therapeutics
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins,which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. $56M / Series C / Mar 04, 2020
Akouos Akouos
Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process,enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner. $105M / Series B / Mar 03, 2020
Triplet Therapeutics Triplet Therapeutics
Triplet is developing transformative therapies that treat repeat expansion disorders at their source. $49M / Series A / Dec 17, 2019
ZielBio ZielBio
ZielBio is an early-stage biotechnology company that identifies novel high-value disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind combines the power of functional, high throughput screening with large content data analytics to identify high-value targets. They havea promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind.ZielBio was founded in 2011 and is based in Charlottesville, Virginia, United States. $25.1M / Series A / Sep 26, 2019
See all 47 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Renewable Energy
Software
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Music
Art
Real Estate
Sporting Goods
Manufacturing
Life Science
Digital Media
FinTech
Finance
Wine and Spirits
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Food and Beverage
Publishing
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Mexico
Tunisia
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Sweden
Romania
Zimbabwe
Zambia
Norway
Tajikistan
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Sudan
Andorra
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Nicaragua
Mauritius
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Seychelles
Moldova
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United States
United Kingdom
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Partners Innovation Fund invest in?

Partners Innovation Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 47 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Partners Innovation Fund?

Public channels for Partners Innovation Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Partners Innovation Fund?

The team at Partners Innovation Fund includes Anne C. Pareti (Associate II), Ellen Jung (Associate II) and Jessica M. Jacobs (Associate, Research & Licensing), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Partners Innovation Fund Partners Innovation Fund Find emails